Alto Neuroscience Inc (Ticker: ANRO US) is a biotechnology company specializing in the development of personalized and highly effective treatment options for mental health conditions. Utilizing an AI-enabled biomarker platform, Alto Neuroscience combines information on patients' brain activity and behavior to match patients with the most suitable product candidates, aiming to improve neuropsychiatric care.

Alto Neuroscience Inc will list on the New York Stock Exchange in the United States. The firm plans to offer 6.7 million shares, with an expected price range of USD 14.00 - 16.00 per share. The total offer size is estimated to be USD 107.20 million. The offering is managed by Jefferies & Co (Left Lead), Cowen & Co, Stifel Nicolaus & Co Inc, and William Blair & Co LLC. The company also includes a greenshoe facility of 15%, amounting to 1.0 million shares. Alto Neuroscience expects to commence trading on February 2, 2024.